Recursion Pharmaceuticals (NASDAQ:RXRX), an AI-enabled clinical-stage drug discovery company, closed at $2.83, up 3.86%. The stock rose after the company said it reached FDA alignment on the REC-4881 Phase 3 design, and investors are watching for further regulatory detail. Tradin
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
